AWHL catalyst calendar

Aspira Women's Health Inc.

Upcoming catalysts
2
Cash runway
4 months
Cash & investments
$0M
Phase 3 programs
3

Aspira Women's Health Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: In Vitro & In Vivo Diagnostic Substances.

The next scheduled catalyst is Next quarterly earnings (projected) on November 21, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
November 21, 2026 est. Next quarterly earnings (projected) Earnings —
June 1, 2030 Evaluation of the Efficacy, Safety, and Tolerability of LevoCept Trial Milestone Phase 3

Track AWHL alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open AWHL in the tracker

Recent history

DateEventTypePhase
July 15, 2026 8-K filed: Material agreement Corporate —
July 7, 2026 8-K/A filed: Leadership change Corporate —
June 22, 2026 8-K filed: Leadership change Corporate —
June 9, 2026 8-K filed: Material agreement Corporate —
May 26, 2026 8-K filed: Material agreement Corporate —
April 30, 2026 8-K filed: Leadership change Corporate —
March 25, 2026 8-K/A filed: Material agreement Corporate —
January 30, 2026 8-K filed: Material agreement Corporate —
December 31, 2025 8-K filed: Reg FD disclosure Filing —
December 23, 2025 8-K filed: Material agreement Corporate —
December 22, 2025 8-K filed: Material agreement Corporate —
November 14, 2025 Quarterly results filed (8-K) Earnings —
November 3, 2025 8-K/A filed: Material agreement Corporate —
October 15, 2025 8-K filed: Other event Filing —
September 25, 2025 8-K filed: Material agreement Corporate —
September 18, 2025 8-K filed: Material agreement, Other event Corporate —
September 3, 2025 8-K filed: Leadership change Corporate —
August 13, 2025 Quarterly results filed (8-K) Earnings —
July 15, 2025 8-K filed: Leadership change Corporate —
June 11, 2025 8-K filed: Other event Filing —
May 19, 2025 Quarterly results filed (8-K) Earnings —
April 16, 2025 8-K filed: Listing / standard notice Corporate —
September 22, 2022 Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS Trial Milestone Phase 3
December 30, 2019 A PK Study Comparing VeraCept vs. ParaGard Intrauterine Devices (IUDs) Trial Milestone Phase 3
July 17, 2018 Evaluation of the Efficacy and Safety of LevoCept Trial Milestone Phase 2
May 15, 2017 Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.